Guobang Pharma Past Earnings Performance

Past criteria checks 4/6

Guobang Pharma has been growing earnings at an average annual rate of 2.4%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 8.7% per year. Guobang Pharma's return on equity is 8.9%, and it has net margins of 12.3%.

Key information

2.4%

Earnings growth rate

-0.9%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate8.7%
Return on equity8.9%
Net Margin12.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Calculating The Fair Value Of Guobang Pharma Ltd. (SHSE:605507)

Aug 26
Calculating The Fair Value Of Guobang Pharma Ltd. (SHSE:605507)

These 4 Measures Indicate That Guobang Pharma (SHSE:605507) Is Using Debt Extensively

Jul 24
These 4 Measures Indicate That Guobang Pharma (SHSE:605507) Is Using Debt Extensively

Guobang Pharma Ltd. (SHSE:605507) Analysts Just Cut Their EPS Forecasts Substantially

May 21
Guobang Pharma Ltd. (SHSE:605507) Analysts Just Cut Their EPS Forecasts Substantially

Fewer Investors Than Expected Jumping On Guobang Pharma Ltd. (SHSE:605507)

Apr 18
Fewer Investors Than Expected Jumping On Guobang Pharma Ltd. (SHSE:605507)

We Think Guobang Pharma (SHSE:605507) Is Taking Some Risk With Its Debt

Mar 25
We Think Guobang Pharma (SHSE:605507) Is Taking Some Risk With Its Debt

Revenue & Expenses Breakdown

How Guobang Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:605507 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 245,714702333188
30 Jun 245,432660367186
31 Mar 245,278617361181
31 Dec 235,349612358191
30 Sep 235,661689401225
30 Jun 235,827783383208
31 Mar 235,955915358213
31 Dec 225,721921352198
30 Sep 225,405906312184
30 Jun 224,966823302173
31 Mar 224,539721313154
31 Dec 214,505706299155
30 Sep 214,273694277146
30 Jun 214,317741259143
31 Mar 214,449834316170
31 Dec 204,206810241137
31 Dec 193,802315243124
31 Dec 183,279211216103
31 Dec 172,90517820295

Quality Earnings: 605507 has high quality earnings.

Growing Profit Margin: 605507's current net profit margins (12.3%) are higher than last year (12.2%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 605507's earnings have grown by 2.4% per year over the past 5 years.

Accelerating Growth: 605507's earnings growth over the past year (1.9%) is below its 5-year average (2.4% per year).

Earnings vs Industry: 605507 earnings growth over the past year (1.9%) exceeded the Pharmaceuticals industry -0.8%.


Return on Equity

High ROE: 605507's Return on Equity (8.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies